ViiV Healthcare announces FDA approval of the first complete long-acting regimen for HIV treatment
Cabenuva allows virologically suppressed adults with HIV to maintain viral suppression with 12 dosing days per year
Cabenuva allows virologically suppressed adults with HIV to maintain viral suppression with 12 dosing days per year
Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide
Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021
BLENREP is the fifth major medicine approval for GSK in 2020
Collaboration combines innovative plant-based and adjuvant technologies to develop and produce a COVID-19 candidate vaccine
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019
Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study